Clinical Trials Directory

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.

Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis (Core Part) followed by extended treatment with open-label BAF312 to obtain data on long-term safety, tolerabiilty and efficacy (Extension Part).

Stanford is now accepting new patients for this trial.


  • drug : Placebo
  • drug : BAF312

Phase: Phase 3


Ages Eligible For Study:

18 Years - 60 Years

Inclusion Criteria

- Prior history of relapsing remitting MS - SPMS defined as progressive increase of disability over at least 6 months - EDSS score of 3.0 to 6.5 - No relapse of corticosteroid treatment within 3 months

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Angela Campbell

Footer Links: